Recent GRI News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/25/2024 05:15:14 AM
- GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF) • GlobeNewswire Inc. • 11/21/2024 01:45:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/15/2024 09:16:18 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/14/2024 09:27:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2024 09:24:37 PM
- GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis • GlobeNewswire Inc. • 11/14/2024 09:20:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2024 09:16:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2024 12:35:47 PM
- GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024 • GlobeNewswire Inc. • 10/24/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/22/2024 08:21:46 PM
- GRI Bio Announces Exercise of Warrants • GlobeNewswire Inc. • 10/21/2024 09:35:00 PM
- GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF) • GlobeNewswire Inc. • 10/16/2024 12:45:00 PM
- GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis • GlobeNewswire Inc. • 10/07/2024 12:30:00 PM
- GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions • GlobeNewswire Inc. • 09/30/2024 12:30:00 PM
- GRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in Australia • GlobeNewswire Inc. • 09/26/2024 12:00:00 PM
- GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment • GlobeNewswire Inc. • 09/25/2024 12:45:00 PM
- GRI Bio Participates in Virtual Investor KOL Connect Segment • GlobeNewswire Inc. • 09/18/2024 01:00:00 PM
- GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/05/2024 12:45:00 PM
- GRI Bio to Present at the 2024 European Respiratory Congress • GlobeNewswire Inc. • 09/04/2024 12:45:00 PM
- GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/14/2024 12:05:00 PM
- GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series • GlobeNewswire Inc. • 07/15/2024 01:05:00 PM
- GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment • GlobeNewswire Inc. • 07/11/2024 01:20:00 PM
- GRI Bio Regains Compliance with Nasdaq • GlobeNewswire Inc. • 07/08/2024 01:05:00 PM
- GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine • GlobeNewswire Inc. • 07/02/2024 01:05:00 PM
North Bay Resources Commences Fran Gold Winter Ore Shipment to Bishop Gold Mill, California • NBRI • Dec 2, 2024 9:07 AM
VAYK Reached Agreement on Terms to Acquire $1 Million Company for Disruptive Airbnb Strategy • VAYK • Dec 2, 2024 9:00 AM
ILUS Announces Completion of QIND Acquisition by Fusion Fuel (NASDAQ: HTOO) • ILUS • Nov 27, 2024 12:35 PM
Cannabix Technologies Receives Positive Testing Certification for Breath Logix Autonomous Alcohol Breathalyzer • BLO • Nov 26, 2024 8:48 AM
BioQuest, Inc. and BotMakers Expand AI Marketing Services with SpeedLeads XL and MarketScope XL. Bioquest Corp. and BotMakers, Inc. are Partnered to Expand AI Marketing Services with SpeedLead XL and MarketScope XL • BQST • Nov 26, 2024 8:00 AM
BNCM Announces its Q3 and 9-Month Growth Results for 2024 • BNCM • Nov 26, 2024 7:03 AM